New Fibromyalgia Treatments Emerge from Psilocybin to Nerve Stimulation

Fibromyalgia (FM) is a chronic nociplastic pain syndrome affecting an estimated 2–4% of the global population. Characterized by widespread musculoskeletal pain, debilitating fatigue, non-restorative sleep, and cognitive impairment—often called 'fibro fog'—it substantially erodes quality of life. Despite decades of research, no single treatment reliably controls symptoms across patients, making this annual review from the Pain Study Group of the Italian Society of Rheumatology a valuable clinical compass.

This 2026 review surveyed emerging pharmacological and non-pharmacological interventions published over the prior year. Low-dose naltrexone (LDN) continues to attract attention for its proposed ability to modulate microglial activity and reduce central sensitization, offering a novel mechanism distinct from traditional analgesics. Cannabinoids received renewed investigation for symptom control, and early-phase studies are now probing psilocybin and other serotonergic psychedelics as neuromodulatory tools—a significant conceptual shift in the field. Intravenous lidocaine, while still considered in refractory cases, has not seen its evidence base meaningfully expand. Nutraceuticals and antioxidant compounds targeting mitochondrial dysfunction and oxidative stress are also attracting growing research interest.

Non-pharmacological strategies continue to form the backbone of FM management. Supervised exercise programs and digitally supported rehabilitation emerged as high-priority interventions, supported by recent trial data on adherence and efficacy. Neuromodulation approaches—particularly non-invasive brain stimulation (e.g., transcranial magnetic stimulation) and vagal nerve stimulation—are gaining scientific momentum. Body-oriented and complementary therapies are also being explored for their effects on pain perception and emotional regulation.

The overarching message is clear: FM demands a biopsychosocial, multimodal framework tailored to each patient's symptom profile and comorbidities. The authors call for improved patient phenotyping and identification of treatment-response predictors to advance precision medicine in FM.

As a review based solely on the abstract, specific effect sizes, trial numbers, and head-to-head comparisons are not available, limiting the ability to rank interventions by strength of evidence.